• For patients who have taken advantage of the anti

  2024-11-18

  

  For patients who have taken advantage of the anti-TKIs and whose follow-up has been succeeded, some partial response has been noticed with 45% (9/20) for gefitinib, 39% (9/23) for erlotinib and 56.5% (13/23) for crizotinib. A disease progression has also been observed with 35% (7/20) for gefitinib,

• The synthetic route to M developed by Rice

  2024-11-18

  

  The synthetic route to M100907 developed by Rice was utilized, however, the chiral resolution was carried out at an earlier stage to provide the possibility of introducing different substituents onto the piperidinyl group. The conditions for this resolution were different from previously reported.

• Pituitary adenylate cyclase activating polypeptide PACAP

  2024-11-18

  

  Pituitary adenylate cyclase-activating polypeptide (PACAP) is a member of the secretin/growth hormone-releasing hormone (GHRH)/vasoactive intestinal peptide (VIP) family, with potent anti-inflammatory and potent cytoprotective properties [[6], [7], [8], [9], [10], [11], [12], [13]]. PACAP exists as

• br Conflicts of interest br Acknowledgments br

  2024-11-18

  

  Conflicts of interest Acknowledgments Significance Introduction Androgen receptor (AR) plays a paramount role in the onset and progression of prostate cancer (PC) (Burnstein, 2005, Lonergan and Tindall, 2011, Watson et al., 2015). This very facet underlies androgen deprivation therapy (A

• Comparatively cell based assays appear to be

  2024-11-18

  

  Comparatively, cell-based assays appear to be the most sensitive method to detect patient autoantibodies directed at neurotransmitter receptors. Leite et al. demonstrated that many α-BTX RIA seronegative myasthenic patients do have autoantibodies against the AChR when a highly sensitive immunofluore

• br Conclusion There have been multiple

  2024-11-18

  

  Conclusion There have been multiple clinical trials and pre-clinical studies that have tested the utility of 5ARIs in treating prostate disease, as summarized in Fig. 1. Inhibiting androgen action through the use of finasteride and dutasteride has been established as a valuable resource for physi

• The identification of novel kinase inhibitor scaffolds is hi

  2024-11-18

  

  The identification of novel kinase inhibitor scaffolds is highly desirable in order to develop selective kinase inhibitors. Small-molecule inhibitors of Interleukin-2-inducible T-cell kinase (Itk) that are based on the 3-aminopyridin-2-one fragment 1 have been reported. Despite derivatisation of 1 y

• br ASK in Huntington s disease and other polyglutamine disea

  2024-11-18

  

  ASK1 in Huntington's disease and other polyglutamine diseases The polyglutamine (polyQ) diseases are a group of inherited neurodegenerative disorders caused by the expansion of cytosine-adenine-guanine (CAG) trinucleotide repeats in the coding regions of specific genes, leading to the production

• br Introduction Quenchbody Q body immunoassay is a

  2024-11-15

  

  Introduction Quenchbody (Q-body) immunoassay is a novel biosensing technology that uses the quenching of fluorescence by intrinsic tryptophan (Trp) residues in antibody variable regions when dye(s) are conjugated to an antibody or antibody fragments in appropriate position, and de-quenching while

• Aberrant lipid levels are associated with various disorders

  2024-11-15

  

  Aberrant lipid levels are associated with various disorders, including vascular diseases and diabetes. Furthermore, important events support the idea that lipids, especially cholesterol and its derivatives, have a fundamental role in the physiopathology of AD. The Sorafenib is rich in cholesterol,

• Mechanistically NAergic signaling in the VTA

  2024-11-15

  

  Mechanistically, NAergic signaling in the VTA modulates neuronal activity presumably via α1-AR. The majority of α1-ARs are found in the VTA are located presynaptically on unmyelinated droperidol and axon terminals of glutamatergic and GABAergic neurons. However, α1-ARs are also found on neuronal de

• We also demonstrate that PACAP treatment dose

  2024-11-15

  

  We also demonstrate that PACAP treatment dose-dependently disrupts performance in the 5CSRTT, suggestive of attentional deficits, another core feature of mood and anxiety disorders. Treatment with PACAP (.5–1.0 µg) decreased the percentage of correct responses, increased the percentage of trials in

• A borderline significant effect of women s age

  2024-11-15

  

  A borderline significant effect of women's age has been observed for ADA6 only. For ADA2 the proportion of the *1/*1 genotype is 69.4% in women aged ≤36 years vs. 66.9% in women aged ≥36 years (p=0.944). The proportion of ADA6*1 allele carriers is 32.6% in women aged ≤36 years vs. 49. 8 in women age

• Our analysis has devoted limited attention to the

  2024-11-14

  

  Our analysis has devoted limited attention to the standard corporate tax scheme with deductibility for interest payments that is in place in most countries. A conventional corporate tax scheme offers partial deduction of capital costs, and can be interpreted as a change in the degree of capital cost

• The role of DHT in early teleost embryogenesis

  2024-11-14

  

  The role of DHT in early teleost embryogenesis is not entirely clear or established, however additional studies that treat fish embryos to DHT or to specific srd5a inhibitors at critical stages of development (i.e. prior to sex differentiation) will shed light on the early functions of this androgen

16370 records 70/1092 page Previous Next First page 上5页 6667686970 下5页 Last page